BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 36841313)

  • 1. Identification of Potent Small-Molecule PCSK9 Inhibitors Based on Quantitative Structure-Activity Relationship, Pharmacophore Modeling, and Molecular Docking Procedure.
    Mahmoudi A; Butler AE; Banach M; Jamialahmadi T; Sahebkar A
    Curr Probl Cardiol; 2023 Jun; 48(6):101660. PubMed ID: 36841313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive computational study in the identification of novel potential cholesterol lowering agents targeting proprotein convertase subtilisin/kexin type 9.
    Maliwal D; Pissurlenkar RRS; Telvekar V
    J Biomol Struct Dyn; 2024 Jun; 42(9):4656-4667. PubMed ID: 37309035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brazilin from
    Iqbal M; Hasanah N; Arianto AD; Aryati WD; Puteri MU; Saputri FC
    Adv Pharmacol Pharm Sci; 2023; 2023():5932315. PubMed ID: 37860715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deciphering the Interactions of Bioactive Compounds in Selected Traditional Medicinal Plants against Alzheimer's Diseases via Pharmacophore Modeling, Auto-QSAR, and Molecular Docking Approaches.
    Ojo OA; Ojo AB; Okolie C; Nwakama MC; Iyobhebhe M; Evbuomwan IO; Nwonuma CO; Maimako RF; Adegboyega AE; Taiwo OA; Alsharif KF; Batiha GE
    Molecules; 2021 Apr; 26(7):. PubMed ID: 33915968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of Novel Anoctamin1 (ANO1) Inhibitors Using 3D-QSAR Pharmacophore Modeling and Molecular Docking.
    Lee YH; Yi GS
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30336555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Allosteric Site of PCSK9 Enzyme for the Identification of Small Molecule Inhibitors: An In Silico Drug Repurposing Study.
    Charbe NB; Zacconi FC; Kowthavarapu VK; Gupta C; Palakurthi SS; Satheeshkumar R; Lokwani DK; Tambuwala MM; Palakurthi S
    Biomedicines; 2024 Jan; 12(2):. PubMed ID: 38397888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacophore Based 3D-QSAR, Virtual Screening and Docking Studies on Novel Series of HDAC Inhibitors with Thiophen Linker as Anticancer Agents.
    Patel P; Singh A; Patel VK; Jain DK; Veerasamy R; Rajak H
    Comb Chem High Throughput Screen; 2016; 19(9):735-751. PubMed ID: 27487787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacophore generation, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on benzamide analogues as FtsZ inhibitors.
    Tripathy S; Azam MA; Jupudi S; Sahu SK
    J Biomol Struct Dyn; 2018 Sep; 36(12):3218-3230. PubMed ID: 28938860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
    Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW
    J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based pharmacophore modeling, virtual screening and simulation studies for the identification of potent anticancerous phytochemical lead targeting cyclin-dependent kinase 2.
    Sharma M; Sharma N; Muddassir M; Rahman QI; Dwivedi UN; Akhtar S
    J Biomol Struct Dyn; 2022; 40(20):9815-9832. PubMed ID: 34151738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Combined Approach of Pharmacophore Modeling, QSAR Study, Molecular Docking and In silico ADME/Tox Prediction of 4-Arylthio & 4-Aryloxy-3- Iodopyridine-2(1H)-one Analogs to Identify Potential Reverse Transcriptase Inhibitor: Anti-HIV Agents.
    Panigrahi D; Mishra A; Sahu SK; Azam MA; Vyshaag CM
    Med Chem; 2022; 18(1):51-87. PubMed ID: 33319692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3D-QSAR-Based Pharmacophore Modeling, Virtual Screening, and Molecular Docking Studies for Identification of Tubulin Inhibitors with Potential Anticancer Activity.
    Mirzaei S; Ghodsi R; Hadizadeh F; Sahebkar A
    Biomed Res Int; 2021; 2021():6480804. PubMed ID: 34485522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
    Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacophore-based virtual screening approach for identification of potent natural modulatory compounds of human Toll-like receptor 7.
    Gupta CL; Babu Khan M; Ampasala DR; Akhtar S; Dwivedi UN; Bajpai P
    J Biomol Struct Dyn; 2019 Nov; 37(18):4721-4736. PubMed ID: 30661449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
    Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
    J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking, density functional and molecular dynamics simulation study.
    Choubey SK; Jeyaraman J
    J Mol Graph Model; 2016 Nov; 70():54-69. PubMed ID: 27668885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D QSAR, pharmacophore and molecular docking studies of known inhibitors and designing of novel inhibitors for M18 aspartyl aminopeptidase of Plasmodium falciparum.
    Kumari M; Chandra S; Tiwari N; Subbarao N
    BMC Struct Biol; 2016 Aug; 16():12. PubMed ID: 27534744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove.
    Evison BJ; Palmer JT; Lambert G; Treutlein H; Zeng J; Nativel B; Chemello K; Zhu Q; Wang J; Teng Y; Tang W; Xu Y; Rathi AK; Kumar S; Suchowerska AK; Parmar J; Dixon I; Kelly GE; Bonnar J
    Bioorg Med Chem; 2020 Mar; 28(6):115344. PubMed ID: 32051094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development, evaluation and application of 3D QSAR Pharmacophore model in the discovery of potential human renin inhibitors.
    John S; Thangapandian S; Arooj M; Hong JC; Kim KD; Lee KW
    BMC Bioinformatics; 2011 Dec; 12 Suppl 14(Suppl 14):S4. PubMed ID: 22372967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.